Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22630352 | 1.00 | L3MBTL3 (0.37) | L3MBTL3ROCK2ALDH1A1TSHRSMYD3 | |
| SCHEMBL22629293 | 1.00 | L3MBTL3 (0.37) | L3MBTL3ROCK2ALDH1A1TSHRSMYD3 | |
| SCHEMBL24161970 | 0.80 | ALDH1A1 (0.36) | L3MBTL3ALDH1A1TSHR | |
| SCHEMBL890380 | 0.79 | CHRNB2 (0.36) | TSHRL3MBTL1 | |
| SCHEMBL4279 | 0.79 | — | — | |
| SCHEMBL1506461 | 0.79 | CHRNB2 (0.36) | TSHRL3MBTL1 | |
| SCHEMBL1060400 | 0.79 | CHRNB2 (0.36) | TSHRL3MBTL1 | |
| SCHEMBL4008610 | 0.78 | LMNA (0.43) | L3MBTL3ALDH1A1TSHR | |
| SCHEMBL12412594 | 0.78 | L3MBTL3 (0.38) | L3MBTL3ROCK2L3MBTL1 | |
| SCHEMBL5065495 | 0.78 | LMNA (0.43) | L3MBTL3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023277604-A1 | NOVEL COMPOUND FOR CAPPING LAYER, AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | 주식회사 동진쎄미켐 | 2023-01-05 | — | — | WO | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | L3MBTL3 4163/4885ROCK2 1376/4885ALDH1A1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.